Cortical Labs

Cortical Labs' CL1 biological computer gains significant traction in both neuromorphic computing and drug discovery markets, driven by its unique biological fidelity and energy efficiency. Key partnerships expand rapidly, pushing revenue to $50M+ by 2028 and justifying a $600M+ valuation (4x current estimated $150M) as the company establishes itself as a leader in the nascent biological computing space.

Cortical Labs continues to make steady progress with its CL1 platform, securing additional research and early commercial customers. Growth is solid but constrained by the high regulatory barrier and the long sales cycles inherent in deep tech. The company reaches ~$20M in revenue by 2028, leading to a $300M valuation (2x current estimated $150M) in a subsequent funding round or acquisition.

Despite early technological promise, Cortical Labs struggles to overcome the high regulatory hurdles and faces intense competition from well-funded incumbents like Intel and Neuralink, who either develop competing solutions or acquire smaller players. High capital intensity leads to a down round or a fire sale, resulting in a $30M valuation (80% below current estimated $150M) and significant loss of common stock value for employees.